Clinuvel Pharmaceuticals : program discussed at Light and Life 2019 Conference

Company Announcement

ASX:	CUV
Nasdaq International Designation: CLVLY
XETRA-DAX:	UR9

CLINUVEL's program discussed at first EU-US joint conference on photomedicine, Light and Life 2019

Melbourne, Australia and Leatherhead, UK, 22 August 2019

CLINUVEL PHARMACEUTICALS LTD today announced that its program in systemic photoprotection will be discussed and presented at the first European-American meeting of the International Congress on Photobiology and Congress of the European Society for Photobiology, Light and Life, held in Barcelona, Spain, from 25-30 August.

The Light and Life conference gives CLINUVEL the opportunity to get feedback on its development program in melanocortins from both European and US experts in photomedicine. As part of the conference, CLINUVEL is convening both a symposium and keynote lecture on photomedicine for the attending medical community. To increase its engagement with expert researchers and clinicians interested in CLINUVEL's R&D stages, the Company is hosting exhibition space.

"At this stage of development, it is timely that the Company engages with a wider audience, including directly with senior academic experts and their successors," CLINUVEL's European General Manager, Lachlan Hay said.

"Light and Life is a unique event where experts from across the globe will congregate to evaluate advances in photomedicine. Prior to lending support to the event, CLINUVEL had received numerous requests to increase the awareness of its mission and focus in photomedicine, since very few companies are active in this domain," Mr Hay said.

- End -

More details on Light and Life 2019, including the full conference program, can be found at https://www.photobiology2019.org/.

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-

DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore, with the UK acting as the EU distribution centre. For more information go to http://www.clinuvel.com.

SCENESSE® is a registered trademark of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor enquiries https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2018 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts and estimates is available on request. Past performance is not an indicator of future performance.

www.clinuvel.com
Suite 3, Level 11	T [phone]
535 Bourke Street	F [phone]

Melbourne

Victoria, Australia, 3000